Lamivudine (Compound)

Synonyms:lamivudine, 134678-17-4, Epivir, Zeffix, Heptovir, Epivir-HBV, 136891-12-8, 3TC, BCH-189, Heptodin, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one, (-)-2'-Deoxy-3'-thiacytidine, VIROLAM, GR-109714X, 3'-Thia-2',3'-dideoxycytidine, GR109714X, GR 109714X, (-)-BCH-189, beta-L-2',3'-Dideoxy-3'-thiacytidine, beta-L-3'-Thia-2',3'-dideoxycytidine, 2',3'-Dideoxy-3'-thiacytidine, CIS-LAMIVUDINE, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one, Lamivudine teva, (-)NGPB-21, BCH 189, (-)-, (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine, 4-Amino-1-(cis-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one, 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE, Hepitec, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one, 4-AMINO-1-[(2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]-2(1H)-PYRIMIDINONE, CHEBI:63577, (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone, 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-, 2T8Q726O95, NSC-760061, Heptivir, Lamivir, Zefix, BCH 189, Lamivudine [USAN:BAN:INN], (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine, 2(1H)-Pyrimidinone, 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, 2(1H)-Pyrimidinone, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, Epivir(TM), HHA & Lamivudine, Lamivudine & GNA, SMR000466319, Epivir (TN), (-)-BCH 189, DTHC, CHEMBL141, HSDB 7155, DRG-0126, 3TC and NV-01, (-)-SddC, DTXSID7023194, Lamivudeine, Lamivudinum, Lamivudine (JAN/USP/INN), 3TC & GNA, 3TC & SST, HHA & 3TC, (+/-)-SddC, CCRIS 9274, NSC620753, UNII-2T8Q726O95, BCH-790, Lamivudine [USAN:USP:INN:BAN], rac-cis-Lamivudine, NCGC00159341-04, Lamivudine- Bio-X, GG-714, MFCD00869739, Lamivudine (EPIVIR), CPD000466319, LAMIVUDINE [MI], (+/-)-3TC, (+/-)-BCH-189, LAMIVUDINE [INN], LAMIVUDINE [JAN], LAMIVUDINE [HSDB], LAMIVUDINE [USAN], LAMIVUDINE [VANDF], LAMIVUDINE [MART.], LAMIVUDINE [USP-RS], LAMIVUDINE [WHO-DD], LAMIVUDINE [WHO-IP], MLS000759424, MLS001424097, MLS006011910, BIDD:GT0033, LAMIVUDINE [EMA EPAR], SCHEMBL109675, AMY384, LAMIVUDINE [EP IMPURITY], LAMIVUDINE [ORANGE BOOK], LAMIVUDINE [EP MONOGRAPH], KIVEXA COMPONENT LAMIVUDINE, HMS2051D21, HMS3259F08, HMS3713C16, LAMIVUDINE [USP MONOGRAPH], EPZICOM COMPONENT LAMIVUDINE, LAMIVUDINUM [WHO-IP LATIN], TEMIXYS COMPONENT LAMIVUDINE, TRIUMEQ COMPONENT LAMIVUDINE, COMBIVIR COMPONENT LAMIVUDINE, HY-B0250, LAMIVUDINE TEVA PHARMA B.V., TRIZIVIR COMPONENT LAMIVUDINE, BBL033871, BDBM50366817, DELSTRIGO COMPONENT LAMIVUDINE, MFCD00870542, s1706, STK801940, lamivudine & TNF-alpha & IFN-gamma, TELURA COMPONENT OF LAMIVUDINE, AKOS005622556, AKOS015854841, LAMIVUDINE COMPONENT OF EPZICOM, LAMIVUDINE COMPONENT OF TEMIXYS, LAMIVUDINE COMPONENT OF TRIUMEQ, Lamivudine, >=98% (HPLC), powder, (-)-BCH189, AC-1416, CCG-100984, DB00709, KS-1073, LAMIVUDINE COMPONENT OF COMBIVIR, LAMIVUDINE COMPONENT OF DUTREBIS, LAMIVUDINE COMPONENT OF TRIZIVIR, NC00234, NC00705, NSC 760061, LAMIVUDINE COMPONENT OF DELSTRIGO, NCGC00159341-05, NCGC00159341-18, NCGC00159341-20, BL164607, EMTRICITABINE IMPURITY C [WHO-IP], L0217, rac-cis-Lamivudine ((2RS,5SR)-Lamivudine), SW197614-3, C07065, D00353, EN300-123034, P17147, AB00639995-06, AB00639995-08, AB00639995_09, Lamivudeine 100 microg/mL in Acetonitrile:Water, Q422631, SR-01000759420, J-700183, Q-201275, SR-01000759420-5, LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINE, LAMIVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA, Z1509637175, Lamivudine, British Pharmacopoeia (BP) Reference Standard, Lamivudine, European Pharmacopoeia (EP) Reference Standard, (2R,5S)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, .beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To, Lamivudine, United States Pharmacopeia (USP) Reference Standard, (+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, (-)-L-2',3'-DIDEOXY-3'-THIACYTIDINE; LAMIVUDINE; EPIVIR, Lamivudine, 1.0 mg/mL in methanol, certified reference material, Lamivudine, Pharmaceutical Secondary Standard; Certified Reference Material, (+/-)-(cis)-4-Amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis), 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-[1,3]-oxathiolan-5-yl]-(1H)-pyrimidin-2-one, 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-Oxathiolan-5-yl]-(1H)-pyrimidin-2-one, cis(+/-)-4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone, Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard, Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard, 1117764-41-6, 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA), 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA), 4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP]

Pubchem:PUBCHEM:60825

Id:cdaa4a6a-4215-5e07-840c-55a1737ee859

Description:nan